Copy Link Print Information

Secukinumab (Anti-Human IL-17A)

13 Cited Publications
Customer Review

Based on 13 publication(s) in Google Scholar

Secukinumab (Anti-Human IL-17A) is a fully human anti-interleukin-17A monoclonal antibody. Anti-Human IL-17A can be used for research in psoriasis pathogenesis.

For research use only. We do not sell to patients.

  • Purity: 98.31%
  • CAS No.: 1229022-83-6
  • Molecular Weight:144 kDa
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Secukinumab (Anti-Human IL-17A)
  • Experimental Validation Results for Secukinumab (Anti-Human IL-17A)
  • Experimental Validation Results for Secukinumab (Anti-Human IL-17A)
  • Experimental Validation Results for Secukinumab (Anti-Human IL-17A)
  • Experimental Validation Results for Secukinumab (Anti-Human IL-17A)
  • Experimental Validation Results for Secukinumab (Anti-Human IL-17A)
  • Experimental Validation Results for Secukinumab (Anti-Human IL-17A)
  • Experimental Validation Results for Secukinumab (Anti-Human IL-17A)
  • Experimental Validation Results for Secukinumab (Anti-Human IL-17A)
  • Experimental Validation Results for Secukinumab (Anti-Human IL-17A)
  • Secukinumab (Anti-Human IL-17A) Chemical Structure
    Secukinumab (Anti-Human IL-17A) Chemical Structure
CAS No.: 1229022-83-6
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Secukinumab (Anti-Human IL-17A):

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Secukinumab (Anti-Human IL-17A)

More
Customer Validation & Images
Cell Proliferation/Viability AssayRT-PCRCell Imaging/StainingHistological Imaging/StainingCell Migration/Invasion Assay
  • Cell Proliferation/Viability Assay
  • RT-PCR
  • Histological Imaging/Staining
  • Cell Proliferation/Viability Assay
  • Cell Imaging/Staining
  • Cell Migration/Invasion Assay
  • Cell Migration/Invasion Assay

All Interleukin Related Isoforms

More

Keywords

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG1 kappa

  • 1/16

    Immobilized N-His-hu IL-17A(24-155) can bind Secukinumab (Anti-Human IL-17A). The EC50 for this effect is 20.63 ng/mL.

  • 1/16

    Flow cytometric analysis of 1X106 Jurkat cells with Secukinumab (Anti-Human IL-17A) (HY-P9927A, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • 1/16

    Secukinumab (Anti-Human IL-17A) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 22;16(1):6753. [Abstract]

    Customer Validation
     The growth curve showed Secukinumab (IL-17a inhibitor, 0.0375-1.5 μg/mL; 48 h) had no impact on mouse tongue muscle cells (mTMCs), mouse tongue squamous cell carcinoma (mTSCC) cells and CaL27 cells proliferation.

  • 1/16

    Secukinumab (Anti-Human IL-17A) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 22;16(1):6753. [Abstract]

    Customer Validation
     Detecting the mRNA level of Desmin for skeletal marker, Col1a1, PDGFRβ, Vimentin and fibroblast activated protein (FAP) for CAFs marker by qRT-PCR to determine the optimal concentration of Secukinumab (0.075-1.5 μg/mL; 48 h) treated.

  • 1/16

    Secukinumab (Anti-Human IL-17A) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 22;16(1):6753. [Abstract]

    Customer Validation
     Representative H&E staining displayed the tumor size in saline-treated TSCC (n = 3 mice/group) and Secukinumab (10 mg/kg; i.p.; once weekly for 5 weeks)-treated TSCC (n = 3 mice/group, left panel). The tumor boundary is marked by black dashed lines. Scale bar = 100 μm. The results showed that Secukinumab significantly impeded tumor growth, resulting in markedly smaller tumor volumes.

  • 1/16

    Secukinumab (Anti-Human IL-17A) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2025 Jul 12:770:152031. [Abstract]

    Customer Validation
     CCK-8 assay for cell viability in MDA-MB-231 cells treated with si-NC, si-KIF20A, si-KIF20A + rhIL-17A (100 μg/L), or Secukinumab (10 μg/mL). RhIL-17A treatment rescued cell viability in si-KIF20A cells, while Secukinumab alone significantly reduced viability compared to si-NC.

  • 1/16

    Secukinumab (Anti-Human IL-17A) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2025 Jul 12:770:152031. [Abstract]

    Customer Validation
     The proliferation level of MDA-MB-231 cells was determined by the Edu staining assay (scale bars = 100 μm). RhIL-17A restored EdU-positive cell numbers in si-KIF20A cells, whereas Secukinumab (10 μg/mL; 24 h) decreased proliferation.

  • 1/16

    Secukinumab (Anti-Human IL-17A) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2025 Jul 12:770:152031. [Abstract]

    Customer Validation
     The migration of MDA-MB-231 cells was detected by wound healing assay (scale bars = 50 μm). si-KIF20A + rhIL-17A exhibited increased wound closure compared to si-KIF20A, while Secukinumab (10 μg/mL; 24 h)-treated cells showed reduced migration.

  • 1/16

    Secukinumab (Anti-Human IL-17A) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2025 Jul 12:770:152031. [Abstract]

    Customer Validation
     Transwell invasion assay (scale bars = 50 μm). RhIL-17A reversed the si-KIF20A-mediated reduction in invasive cells, and Secukinumab (10 μg/mL; 24 h) alone suppressed invasion similarly to si-KIF20A.

  • Secukinumab (Anti-Human IL-17A) Chemical Structure
    1/16
  • Secukinumab (Anti-Human IL-17A)
  • Immobilized N-His-hu IL-17A(24-155) can bind Secukinumab (Anti-Human IL-17A). The EC50 for this effect is 20.63 ng/mL.
  • Flow cytometric analysis of 1X106 Jurkat cells with Secukinumab (Anti-Human IL-17A) (HY-P9927A, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).